• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Scientists identify key kala-azar protein

Snowy Owl

Retired in 2010, In Memoriam
Scientists identify key kala-azar protein

By Sanjit Bagchi, New Delhi, April 27 :

Indian researchers have identified a key protein that plays an important role in regulating the survival, infectivity and drug response of the parasite that causes visceral leishmaniasis - better known as 'kala-azar'.

Kala-azar is the most severe form of leishmaniasis, and is caused by a parasite called Leishmania donovani, which spreads to people through the bite of an infected female sandfly, Scidev.Net reported.

Jitesh P. Iyer and co-workers from the National Institute of Immunology, found that higher levels of an enzyme called cTXNPx made the L. donovani parasite more virulent at certain times in its life cycle.​

Laboratory tests also showed a higher parasite burden in immune cells.

cTXNPx belongs to the group of enzymes that detoxify peroxides, chemicals that are toxic to L. donovani. When humans are infected by L. donovani, their immune cells release hydrogen peroxide to destroy the parasite.

Parasites with higher levels of cTXNPx were more able to withstand high levels of hydrogren peroxide, and were also resistant to an antileishmanial drug.

"This study provides a link between cTXNPx expression to survival, virulence and drug response in L. donovani," the researchers write in a paper published in the April issue of the journal Molecular Microbiology.

"This study invites further studies to explore the plausibility of any new drug molecule targeting this enzyme," said Swapan Jana of the Society for Social Pharmacology.

"The study is impressive - given the emerging drug resistance of Leishmania donovani, it's important to work on the ways to combat the parasite through newer drugs."

Drug-resistance of L. donovani is a major issue in developing countries like India, said Jana.

"Even though different centres have reported different findings, it is a fact that resistance [of L. donovani] to the first line drug sodium antimony gluconate has been increasing since the late 1970s," said Sarman Singh of the All India Institute of Medical Sciences.

Kala-azar is endemic in four Indian states, the worst affected being Bihar. The disease infects about 300,000 people and kills 20,000 in India each year.

"In some areas of Bihar, drug resistance is reported in up to 70 percent of cases,"
added Singh.

--- IANS

http://www.newkerala.com/one.php?action=fullnews&id=53283
 
Back
Top